Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism

被引:165
作者
Lobo, RA
Bush, T
Carr, BR
Pickar, JH
机构
[1] Columbia Presbyterian Med Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA
[2] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
[3] SW Texas State Univ, Med Ctr, Dept Obstet & Gynecol, San Marcos, TX 78666 USA
关键词
conjugated equine estrogens (CEE); medroxyprogesterone acetate (MPA); lower doses; women's HOPE study; hormone replacement therapy (HRT); lipoproteins; lipids; coagulation; carbohydrate metabolism;
D O I
10.1016/S0015-0282(01)01829-5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To determine the effects of lower doses of conjugated equine estrogens (CEE) alone or CEE and medroxyprogesterone acetate (MPA) on lipoproteins, carbohydrate metabolism, and coagulation/fibrinolytic factors. Design: Randomized, double-blind, placebo-controlled study. Setting: Multicenter substudy of the Women's HOPE trial. Patient(s): Seven hundred and forty-nine healthy, postmenopausal women. Intervention(s): Women were randomized to receive the following doses in milligrams per day: 0.625 CEE; 0.625 CEE/2.5 MPA; 0.45 CEE; 0.45 CEE/2.5 MPA; 0.45 CEE/1.5 MPA; 0.3 CEE; 0.3 GEE/1.5 MPA; or placebo. Main Outcome Measure(s): Assessment of lipids, lipoproteins, glucose tolerance, and coagulation/fibrinolytic factors at baseline, cycle 6, and year 1. Result(s): One year of treatment with any of the CEE or CEE/MPA regimens studied increased high-density lipoprotein cholesterol (HDL-C); the 10% increase in HDL-C for the CEE 0.45/MPA 1.5 group was similar to the CEE 0.625/MPA 2.5 group. Low-density lipoprotein cholesterol was significantly reduced in all of the active treatment groups except the CEE 0.3/MPA 1.5 group at cycle 13. Apolipoprotein A-I and triglyceride levels increased and apolipoprotein B levels decreased in all groups. The lipoprotein (a) level was reduced in the CEE 0.45/MPA 2.5, CEE 0.45/MPA 1.5, and CEE 0.625/MPA 2.5 groups. Minimal changes were observed in carbohydrate metabolism for all groups. Fibrinogen and PAI-1 activity decreased and plasminogen activity increased in all groups. Decreases in antithrombin III and protein S activities were significant for all active treatment groups except the CEE 0.3/MPA 1.5 group. Conclusion(s): Lower doses of CEE and CEE/MPA induce favorable changes in lipids, lipoproteins, and hemostatic factors with minimal changes in carbohydrate metabolism. (C) 2001 by American Society for Reproductive Medicine.
引用
收藏
页码:13 / 24
页数:12
相关论文
共 50 条
[1]  
*AM HEART ASS, 1999, 2000 HEART STROK STA, P1
[2]   Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding [J].
Archer, DF ;
Dorin, M ;
Lewis, V ;
Schneider, DL ;
Pickar, JH .
FERTILITY AND STERILITY, 2001, 75 (06) :1080-1087
[3]  
Bachorik P, 1997, HDB LIPOPROTEIN TEST, P145
[4]   PLASMA-LIPOPROTEIN LEVELS AS PREDICTORS OF CARDIOVASCULAR DEATH IN WOMEN [J].
BASS, KM ;
NEWSCHAFFER, CJ ;
KLAG, MJ ;
BUSH, TL .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (19) :2209-2216
[5]  
BERMAN RS, 1997, DRUG INF J, V31, P71
[6]   MENOPAUSE-RELATED CHANGES IN LIPOPROTEINS AND SOME OTHER CARDIOVASCULAR RISK-FACTORS [J].
BONITHONKOPP, C ;
SCARABIN, PY ;
DARNE, B ;
MALMEJAC, A ;
GUIZE, L .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1990, 19 (01) :42-48
[7]   Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: Effects on serum lipoproteins and glucose tolerance during 24 month follow up [J].
Crook, D ;
Godsland, IF ;
Hull, J ;
Stevenson, JC .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (03) :298-304
[8]   Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion [J].
Cucinelli, F ;
Paparella, P ;
Soranna, L ;
Barini, A ;
Cinque, B ;
Mancuso, S ;
Lanzone, A .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (03) :215-223
[9]  
Delmas P D, 1999, J Epidemiol Biostat, V4, P155
[10]   Determinants of long-term hormone replacement therapy and reasons for early discontinuation [J].
Den Tonkelaar, I ;
Oddens, BJ .
OBSTETRICS AND GYNECOLOGY, 2000, 95 (04) :507-512